hepatocellular carcinoma
Conditions
Interventions
Sponsors
Drum Hospital of medical school of Nanjing University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Tumor histological examination confirms advanced HCC, non-surgical resection of hepatocellular carcinoma, visible lesions larger than 1 cm, able to tolerate and complete TACE, radiotherapy, targeted therapy; 2. Age 18-70 years, regardless of gender; 3. Organ status allows clinical trials: Child score =2.5x10^9/L, PLT >=60x10^9/L, Hb >=9.0 g/dL, MID >=1.0x10^9/L; LY >=0.4x10^9/L, LY% >=15%; 4. Blood biochemistry: serum Alb >=30 g/L, serum lipase and amylase 90% (at room temperature); ejection fraction (EF)> 55%; 6. No bleeding and coagulopathy; 7. No contrast agent allergy; 8. Contraception: use of contraception during clinical trials; 9. Sufficient peripheral blood can be obtained through the vein, and there are no other contraindications for lymphocyte collection; 10. Karnofsky functional status score> 60%; Informed consent for one year of ketogenic treatment.
Exclusion criteria
Exclusion criteria: 1. Patients with diabetes; 2. History of hypoglycemia; 3. Patients with porphyria; 4. Patients with pyruvate carboxylase deficiency; 5. Patients with diseases of fatty acid mitochondrial transport disorder; 6. Patients with ß-oxidation deficiency and some special mitochondrial diseases; 7. Patients with severe kidney disease; 8. Imaging and histological diagnosis of extrahepatic metastases or other tumors; 9. Accept liver resection and liver transplantation patients; 10. Patients whose heart and lung function cannot tolerate TACE and radiotherapy; 11. Pregnant or lactating women; 12. Uncontrolled symptoms or other diseases including but not limited to infection, congestive heart failure, unstable angina pectoris, arrhythmia, mental illness or restricting the social environment that meets the requirements or the attending doctor thinks it will bring unpredictable risks; 13. Patients participating in other clinical trials; 14. Other accompanying anti-tumor treatments; 15. The investigator assesses that the patient is unable or unwilling to comply with the requirements of the research protocol; 16. Researchers consider other reasons unsuitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor size;tumor metastasis rate;lifetime; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum AFP; | — |
Countries
China
Contacts
Public ContactDecai Yu
Drum Hospital of Medical School of Nanjing University
Outcome results
None listed